Alios BioPharma is a privately-held biotechnology company located in South San Francisco, CA, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an innovative team of highly experienced scientists and clinical researchers who are developing direct acting antiviral agents against several human viral pathogens of public health importance including respiratory viruses, and other chronic, acute and emerging viral diseases. The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/07/14 | $41,000,000 | Series B |
Novartis Venture Funds Novo Ventures Roche Venture Fund SR One | undisclosed |
